Literature DB >> 8417812

Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.

R S Israeli1, C T Powell, W R Fair, W D Heston.   

Abstract

Recently, a novel M(r) 100,000 prostate-specific membrane glycoprotein (PSM) has been detected by the prostate-specific monoclonal antibody 7E11-C5, raised against the human prostatic carcinoma cell line LNCaP. The PSM antigen is expressed exclusively by normal and neoplastic prostate cells and metastases. We now report the molecular cloning of a full-length 2.65-kilobase complementary DNA encoding the PSM antigen from a human LNCaP complementary DNA library by polymerase chain reaction using degenerate oligonucleotide primers. Analysis of the complementary DNA sequence has revealed that a portion of the coding region, from nucleotide 1250 to 1700, has 54% homology to the human transferrin receptor mRNA. The deduced polypeptide has a putative transmembrane domain enabling the delineation of intra- and extracellular portions of this antigen. In contrast to prostate-specific antigen and prostatic acid phosphatase which are secreted proteins, PSM as an integral membrane protein may prove to be effective as a target for imaging and cytotoxic targeting modalities.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8417812

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  103 in total

1.  Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer.

Authors:  Ziyue Karen Jiang; Makoto Sato; Liu H Wei; Chinghai Kao; Lily Wu
Journal:  Cancer Res       Date:  2011-09-20       Impact factor: 12.701

Review 2.  Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.

Authors:  Michael J Morris; Neeta Pandit-Taskar; Chaitanya Divgi; Steven Larson; Howard I Scher
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

3.  The emergence of radioimmunoscintigraphy for prostate cancer.

Authors:  Thomas E Keane; Inger L Rosner; M Scott Wingo; David G McLeod
Journal:  Rev Urol       Date:  2006

Review 4.  The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

Authors:  Benjamin T Ristau; Denise S O'Keefe; Dean J Bacich
Journal:  Urol Oncol       Date:  2013-12-08       Impact factor: 3.498

Review 5.  Imaging of distant metastases of prostate cancer.

Authors:  Filippo Pesapane; Marcin Czarniecki; Matteo Basilio Suter; Baris Turkbey; Geert Villeirs
Journal:  Med Oncol       Date:  2018-09-14       Impact factor: 3.064

Review 6.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

7.  Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells.

Authors:  J M Corman; E E Sercarz; N K Nanda
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

8.  The Maize Viviparous8 locus, encoding a putative ALTERED MERISTEM PROGRAM1-like peptidase, regulates abscisic acid accumulation and coordinates embryo and endosperm development.

Authors:  Masaharu Suzuki; Susan Latshaw; Yutaka Sato; A Mark Settles; Karen E Koch; L Curtis Hannah; Mikiko Kojima; Hitoshi Sakakibara; Donald R McCarty
Journal:  Plant Physiol       Date:  2008-01-18       Impact factor: 8.340

9.  Transcriptional activation of the human prostatic acid phosphatase gene by NF-kappaB via a novel hexanucleotide-binding site.

Authors:  Stanislav Zelivianski; Richard Glowacki; Ming-Fong Lin
Journal:  Nucleic Acids Res       Date:  2004-07-07       Impact factor: 16.971

Review 10.  Imaging in targeted delivery of therapy to cancer.

Authors:  Gairin Dancey; Richard H Begent; Tim Meyer
Journal:  Target Oncol       Date:  2009-10-08       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.